Search Results

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

• Source: A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential

Record details

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

• Source: Phase I Study Accessing the Safety of Pacritinib in Combination With Talazoparib in Patients With Myeloproliferative Neoplasms Unresponsive to Frontline JAK2 (Janus

Record details

Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.

• Authors : Ye MT; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Wang Y

Subjects: Myelodysplastic-Myeloproliferative Diseases*/Myelodysplastic-Myeloproliferative Diseases*/Myelodysplastic-Myeloproliferative Diseases*/diagnosis ; Myelodysplastic-Myeloproliferative Diseases*/Myelodysplastic-Myeloproliferative Diseases*/Myelodysplastic-Myeloproliferative Diseases*/genetics ; Myeloproliferative Disorders*/Myeloproliferative Disorders*/Myeloproliferative Disorders*/genetics

• Source: Leukemia & lymphoma [Leuk Lymphoma] 2020 Apr; Vol. 61 (4), pp. 963-966. Date of Electronic Publication: 2019 Nov 21.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

A novel JAK2 R564* variant in a patient with thrombocytosis.

• Authors : Villanueva A; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; Poon KS

Subjects: Mutation*; Janus Kinase 2/Janus Kinase 2/Janus Kinase 2/*genetics ; Myeloproliferative Disorders/Myeloproliferative Disorders/Myeloproliferative Disorders/*genetics

• Source: International journal of laboratory hematology [Int J Lab Hematol] 2020 Apr; Vol. 42 (2), pp. e38-e41. Date of Electronic Publication: 2019 Aug 23.Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 101300213 Publication Model: Print-Electronic Cited Medium:

Record details

CALR but Not JAK2 Mutations Are Associated with an Overexpression of Retinoid X Receptor Alpha in Essential Thrombocythemia.

• Authors : Guijarro-Hernández, Ana¹ (AUTHOR) ; Hurtado, Cristina¹ (AUTHOR) ; Larráyoz, María José² (AUTHOR)

• Source: Cancers. Apr2024, Vol. 16 Issue 8, p1511. 9p.

Record details

JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.

• Authors : Isabel Giraldo-Rincón, Ana¹; Naranjo Molina, Sara¹; Gomez-Lopera, Natalia¹

• Source: Colombia Medica. 2023, Vol. 54 Issue 3, p1-12. 12p.

Record details

JAK2 p.V617F Variants in Non-Blood DNA from Patients with Polycythemia Vera.

• Authors : Naoki Mori^1,2 ; Mari Ohwashi-Miyazaki¹; Kentaro Yoshinaga¹

• Source: Turkish Journal of Hematology. 2023, Vol. 40 Issue 3, p220-222. 3p.

Record details

A 68-Year-Old Man with a Cytogenetic Diagnosis of Chronic Myeloid Leukemia and Bone Marrow Findings of Philadelphia Chromosome Translocation Between the Long Arm of Chromosomes 9 and 22, Leading to the BCR-ABL1 Fusion Gene and V617F Mutation in the JAK2 Gene

• Authors : Warsi, Ashraf¹; Alamoudi, Sameer¹; Alsuraihi, Anas K.²

• Source: American Journal of Case Reports. 3/3/2023, Vol. 24, p1-5. 5p.

Record details

Kronik Miyeloproliferatif Hastalık Olgularında JAK2 V617F Mutasyon Sıklığı.

• Authors : ÖZ, Özlem¹

• Source: Journal of Harran University Medical Faculty / Harran Üniversitesi Tıp Fakültesi Dergisi. 2019, Vol. 16 Issue 3, p492-495. 4p.

Record details

Analysis of JAK2 V617F mutation in Tunisian patients with myeloproliferative neoplasms.

• Authors : Chadi, Soumaya¹ (AUTHOR); Dhaouadi, Tarak¹ (AUTHOR) ; Sfar, Imen¹ (AUTHOR)

• Source: European Journal of Inflammation. 4/7/2021, p1-8. 8p.

Record details